Perfluorocarbon nanoparticles: A theranostic platform technology

Gregory M. Lanza, Patrick M. Winter, Shelton D. Caruthers, Michael S. Hughes, Grace Hu, Dipanjan Pan, Anne H. Schmieder, Christine Pham, Samuel A. Wickline

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations

Abstract

Nanomedicine clearly offers unique tools to address intractable medical problems in cancer and cardiovascular disease from entirely new perspectives. Among the theranostic options emerging in this new wave of biotechnology development, the perfluorocarbon nanoparticles have shown robust potential in vivo for diagnosing, characterizing, treating and following proliferating cancers, progressive atherosclerosis, rheumatoid arthritis and much more. These molecular imaging agents have been demonstrated for use with ultrasound, MRI, CT, and SPECT/CT. Moreover, the synergism of imaging for confirmation of therapeutic delivery, for dosimetry, and for noninvasively following early treatment responses is discussed. Image-guided drug delivery based on nanotechnology is emerging as a powerful clinical opportunity, and PFC nanoparticles are among the leading technologies reaching clinical testing today with this potential.

Original languageEnglish
Title of host publicationNanopharmaceutics
Subtitle of host publicationThe Potential Application of Nanomaterials
PublisherWorld Scientific Publishing Co.
Pages293-346
Number of pages54
ISBN (Electronic)9789814368674
ISBN (Print)9789814368667
DOIs
StatePublished - Jan 1 2012

Keywords

  • Angiogenesis
  • Drug delivery
  • Fumagillin
  • MRI
  • Molecular imaging
  • Nanoparticles
  • Nuclear
  • Perfluorocarbon
  • Theranostic
  • Ultrasound

Fingerprint

Dive into the research topics of 'Perfluorocarbon nanoparticles: A theranostic platform technology'. Together they form a unique fingerprint.

Cite this